Evidence map›Paper›PMID 41121194›Full record

ArticleBMC biology2025

Establishment of an imaging-based screening pipeline for the identification of human ribosome biogenesis inhibitors.

Claudia Gafko, Réka Hollandi, Kerstin Dörner, Matteo Rosellini, Ivo Zemp, Peter Horvath, Ulrike Kutay

Abstract read
In one paragraph

Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claudia GafkoInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, 8093, Switzerland.
Réka HollandiSynthetic and Systems Biology Unit, Biological Research Center, Szeged, Hungary.
Kerstin DörnerInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, 8093, Switzerland.
Matteo RoselliniInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, 8093, Switzerland.
Ivo ZempInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, 8093, Switzerland.
Peter HorvathSynthetic and Systems Biology Unit, Biological Research Center, Szeged, Hungary.
Ulrike KutayInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, 8093, Switzerland. ulrike.kutay@bc.biol.ethz.ch.ORCID http://orcid.org/0000-0002-8257-7465

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 51NF40-205601
6 · The paper itself

Abstract

backgroundRibosomes are huge ribonucleoprotein particles that mediate protein synthesis in all organisms. The synthesis of ribosomes is a complex process that involves hundreds of supporting factors in mammalian cells, including proto-oncogenes and tumor suppressors. Dysregulation of ribosome biogenesis can contribute to tumorigenesis, and the increased production of ribosomes in cancer cells is known to promote proliferative cell growth. Therefore, ribosome biogenesis represents an attractive vulnerability of cancer cells that ought to be exploited for the development of anti-cancer drugs. Despite the large number of trans-acting factors promoting ribosome assembly including potentially druggable enzymes, only few chemical inhibitors that act on ribosome biogenesis, especially downstream of pre-rRNA transcription, have been identified to date.

resultsTo enable large-scale screens for chemical compounds that interfere with ribosome biogenesis, we have established a pipeline to perform single-cell, imaging-based screening campaigns using four different readouts, including fluorescent ribosomal protein reporters (RPS2-YFP, RPL29-GFP) and immunofluorescence analyses of the ribosome biogenesis factor ENP1(BYSL), in HeLa cells, a human cancer line. We have assessed the robustness of our high-content screening approach by performing a pilot screen using a library comprising more than 1000 FDA-approved drugs with known targets in other pathways. This pilot screen obtained excellent quality scores and identified ten compounds as hits. These hit compounds likely affect ribosome synthesis indirectly, the majority by inducing DNA damage or by inhibiting the proteasome. We therefore used the identified compounds to establish appropriate counter assays for DNA damage and proteasome inhibition, to exclude common indirect effects in the downstream analysis of such screening campaigns.

conclusionsThe established screening pipelines provide a robust, efficient, and sensitive experimental framework to identify chemical compounds that impair ribosome synthesis. The combination of readouts allows to distinguish effects on pre-rRNA synthesis from downstream effects on ribosome assembly. Established counter assays on DNA damage and protein degradation enable to exclude effects on these pathways, which commonly interfere with ribosome synthesis indirectly. The developed assays are easily scalable to screen libraries of higher complexity in the future.

Indexed as

Antineoplastic AgentsHigh-Throughput Screening AssaysRibosomesDrug Evaluation, PreclinicalHeLa CellsHumansRibosomal ProteinsAntineoplastic AgentsRibosomal ProteinsCancerChemical compound screenDrugHigh-content screeningImage analysisMachine learningMicroscopyRibosomal subunitRibosome synthesisrRNA

Identifiers

PMID41121194
PMCPMC12542422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.